- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:42 | Silo Pharma sets public offering at $0.60 per share and warrant | 1 | Investing.com | ||
| 15:30 | Silo Pharma announces pricing of $2 million public offering | 3 | Seeking Alpha | ||
| 15:18 | Silo Pharma, Inc.: Silo Pharma Announces Pricing of $2 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| Mi | Silo Pharma treibt PTBS-Behandlungsstudie mit Veloxity Labs voran | 1 | Investing.com Deutsch | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Silo Pharma advances PTSD treatment study with Veloxity Labs | 1 | Investing.com | ||
| Mi | Silo Pharma, Inc.: Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 | 98 | GlobeNewswire (Europe) | SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
| Mi | Silo Pharma Signs With Frontage Labs For FDA Requested Safety Study Of SPC-15 | - | RTTNews | ||
| Mi | Silo Pharma macht Fortschritte bei Studien zu nasaler PTBS-Therapie | 1 | Investing.com Deutsch | ||
| Mi | Silo Pharma advances in PTSD nasal therapy trials | 1 | Investing.com | ||
| Mi | Silo Pharma, Inc.: Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories | 104 | GlobeNewswire (Europe) | SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
| Fr | Silo Pharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| Fr | Silo Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 30.04. | Silo Pharma meldet positive präklinische Ergebnisse für SP-26 | 2 | Investing.com Deutsch | ||
| 30.04. | Silo Pharma, Inc.: Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study | 1 | GlobeNewswire (USA) | ||
| 30.04. | EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models | 1 | Benzinga.com | ||
| 29.04. | Silo Pharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 28.04. | Silo Pharma reicht Patent für Alzheimer-Behandlung ein | 1 | Investing.com Deutsch | ||
| 28.04. | Silo Pharma, Inc.: Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug | 1 | GlobeNewswire (USA) | ||
| 25.04. | Silo Pharma files to sell $4.72M shares of common stock, warrants | 4 | Seeking Alpha | ||
| 25.04. | Silo Pharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,70 | -0,85 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| CUREVAC | 3,012 | -0,66 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| AMGEN | 237,90 | +1,32 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| NOVAVAX | 5,460 | +2,40 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| BIOGEN | 106,85 | -0,93 % | BIOGEN INC. - 8-K, Current Report | ||
| ILLUMINA | 71,78 | +2,48 % | Illumina, Inc.: Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 | Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)
GAAP operating margin of 15.8% and non-GAAP operating... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 31,600 | -1,25 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - F-1/A, Registration statement for certain foreign private issuers | ||
| VIKING THERAPEUTICS | 23,700 | -0,34 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,950 | -1,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating... ► Artikel lesen | |
| EDITAS MEDICINE | 1,277 | +3,69 % | Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting | Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,700 | -1,02 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| SAREPTA THERAPEUTICS | 31,050 | -3,03 % | Sarepta Therapeutics' Elevidys Gets Approval In Japan To Treat Duchenne Muscular Dystrophy | WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,016 | +2,73 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,940 | -4,99 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen |
Das Unternehmen SILO PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,314 (-38,76 %) liegt der Kurs bei 0,496 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILO PHARMA INC finden Sie auf Wallstreet Online.